Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

Blood Adv (2021) 5 (16): 3203–3215.

https://doi.org/10.1182/bloodadvances.2021004976

Published: 2021

Includes: Supplemental data

Journal Articles

A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS

Blood Adv (2021) 5 (16): 3066–3075.

https://doi.org/10.1182/bloodadvances.2020004055

Published: 2021

Journal Articles

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL –negative MPN in blast phase

Vikas Gupta, James A. Kennedy, Jose-Mario Capo-Chichi, Soyoung Kim, Zhen-Huan Hu, Edwin P. Alyea, Uday R. Popat, Ronald M. Sobecks, Bart L. Scott, Aaron T. Gerds, Rachel B. Salit, H. Joachim Deeg, Ryotara Nakamura, Wael Saber

Blood Adv (2020) 4 (21): 5562–5573.

https://doi.org/10.1182/bloodadvances.2020002727

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation

Juliane Grimm, Madlen Jentzsch, Marius Bill, Karoline Goldmann, Julia Schulz, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind

Blood Adv (2020) 4 (16): 3864–3874.

https://doi.org/10.1182/bloodadvances.2020001904

Published: 2020

Includes: Supplemental data

Journal Articles

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Giacomo Coltro, Giada Rotunno, Lara Mannelli, Carmela Mannarelli, Sara Fiaccabrino, Simone Romagnoli, Niccolò Bartalucci, Enrica Ravenda, Eleonora Gelli, Emanuela Sant’Antonio, Mrinal M. Patnaik, Ayalew Tefferi, Alessandro M. Vannucchi, Paola Guglielmelli

Blood Adv (2020) 4 (15): 3677–3687.

https://doi.org/10.1182/bloodadvances.2020002175

Published: 2020

Includes: Supplemental data

Journal Articles

Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia

Douglas R. A. Silveira, Lynn Quek, Itamar S. Santos, Anna Corby, Juan L. Coelho-Silva, Diego A. Pereira-Martins, Grant Vallance, Benjamin Brown, Luciana Nardinelli, Wellington F. Silva, Elvira D. R. P. Velloso, Antonio R. Lucena-Araujo, Fabiola Traina, Andy Peniket, Paresh Vyas, Eduardo M. Rego, Israel Bendit, Vanderson Rocha

Blood Adv (2020) 4 (10): 2339–2350.

https://doi.org/10.1182/bloodadvances.2019001419

Published: 2020

Includes: Supplemental data

Journal Articles

Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma

Blood Adv (2020) 4 (10): 2236–2244.

https://doi.org/10.1182/bloodadvances.2019001275

Published: 2020

Includes: Supplemental data

Journal Articles

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Yu-Hung Wang, Chien-Chin Lin, Chi-Yuan Yao, Chia-Lang Hsu, Hsin-An Hou, Cheng-Hong Tsai, Wen-Chien Chou, Hwei-Fang Tien

Blood Adv (2020) 4 (4): 644–654.

https://doi.org/10.1182/bloodadvances.2019001185

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial

Giacomo Gianfaldoni, Francesco Mannelli, Tamara Intermesoli, Sara Bencini, Damiano Giupponi, Giorgio Farina, Ilaria Cutini, Maria Ida Bonetti, Arianna Masciulli, Ernesta Audisio, Dario Ferrero, Chiara Pavoni, Anna Maria Scattolin, Alberto Bosi, Alessandro Rambaldi, Renato Bassan

Blood Adv (2020) 4 (2): 301–311.

https://doi.org/10.1182/bloodadvances.2019000406

Published: 2020

Includes: Supplemental data

Journal Articles

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Blood Adv (2020) 4 (2): 253–262.

https://doi.org/10.1182/bloodadvances.2019000875

Published: 2020

Journal Articles

Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern

Gerbrig Berger, Mylene Gerritsen, Guoqiang Yi, Theresia N. Koorenhof-Scheele, Leonie I. Kroeze, Marian Stevens-Kroef, Kenichi Yoshida, Yuichi Shiraishi, Eva van den Berg, Hein Schepers, Geert Huls, André B. Mulder, Seishi Ogawa, Joost H. A. Martens, Joop H. Jansen, Edo Vellenga

Blood Adv (2019) 3 (20): 3111–3122.

https://doi.org/10.1182/bloodadvances.2019000518

Published: 2019

Includes: Supplemental data

Journal Articles

The impact of response kinetics for multiple myeloma in the era of novel agents

Blood Adv (2019) 3 (19): 2895–2904.

https://doi.org/10.1182/bloodadvances.2019000432

Published: 2019

Includes: Supplemental data

Journal Articles

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study

Sarah Wagner, Jayakumar Vadakekolathu, Sarah K. Tasian, Heidi Altmann, Martin Bornhäuser, A. Graham Pockley, Graham R. Ball, Sergio Rutella

Blood Adv (2019) 3 (8): 1330–1346.

https://doi.org/10.1182/bloodadvances.2018030726

Published: 2019

Includes: Supplemental data

Journal Articles

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

Blood Adv (2019) 3 (5): 744–750.

https://doi.org/10.1182/bloodadvances.2018022806

Published: 2019

Journal Articles

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL

Blood Adv (2019) 3 (2): 148–157.

https://doi.org/10.1182/bloodadvances.2018025718

Published: 2019

Includes: Supplemental data

Journal Articles

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

Blood Adv (2019) 3 (1): 83–95.

https://doi.org/10.1182/bloodadvances.2018026658

Published: 2019

Includes: Supplemental data

Journal Articles

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models

Animesh Pardanani, Sahrish Shah, Francesco Mannelli, Yoseph C. Elala, Paola Guglielmelli, Terra L. Lasho, Mrinal M. Patnaik, Naseema Gangat, Rhett P. Ketterling, Kaaren K. Reichard, Curtis A. Hanson, Alessandro M. Vannucchi, Ayalew Tefferi

Blood Adv (2018) 2 (21): 2964–2972.

https://doi.org/10.1182/bloodadvances.2018026245

Published: 2018

Journal Articles

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy

Alex Aleshin, Peter L. Greenberg

Blood Adv (2018) 2 (20): 2787–2797.

https://doi.org/10.1182/bloodadvances.2018015834

Published: 2018

Journal Articles

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma

Tilmann Bochtler, Maximilian Merz, Thomas Hielscher, Martin Granzow, Korbinian Hoffmann, Alwin Krämer, Marc-Steffen Raab, Jens Hillengass, Anja Seckinger, Christoph Kimmich, Tobias Dittrich, Carsten Müller-Tidow, Dirk Hose, Hartmut Goldschmidt, Ute Hegenbart, Anna Jauch, Stefan O. Schönland

Blood Adv (2018) 2 (20): 2607–2618.

https://doi.org/10.1182/bloodadvances.2018023200

Published: 2018

Includes: Supplemental data

NARROW

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL –negative MPN in blast phase

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation

RAS / CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia

Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma

A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern

The impact of response kinetics for multiple myeloma in the era of novel agents

A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen

Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only